Rupak Desai1, Tarang Parekh2, Upenkumar Patel3, Hee Kong Fong4, Suparn Samani5, Chiranj Patel6, Sejal Savani7, Rajkumar Doshi8, Gautam Kumar9, Rajesh Sachdeva10. 1. Department of Cardiology, Atlanta VA Medical Center, Decatur, GA, USA. Electronic address: drrupakdesai@gmail.com. 2. Department of Health Administration and Policy, George Mason University, Fairfax, VA, USA. 3. Department of Internal Medicine, Nassau University Medical Center, East Meadow, NY, USA. 4. Department of Internal Medicine, University of Missouri-Columbia, Columbia, MO, USA. 5. Department of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ, USA. 6. Memorial Hermann Heart & Vascular Institute Texas Medical Center, Houston, TX, USA. 7. Public Health, New York University, New York, NY, USA. 8. Department of Internal Medicine, University of Nevada School of Medicine, Reno, NV, USA. 9. Department of Cardiology, Atlanta VA Medical Center, Decatur, GA, USA; Department of Cardiology, Emory University School of Medicine, Atlanta, GA, USA. 10. Department of Cardiology, Atlanta VA Medical Center, Decatur, GA, USA; Department of Cardiology, Emory University School of Medicine, Atlanta, GA, USA; Department of Cardiology, Morehouse School of Medicine, Atlanta, GA, USA.
Abstract
BACKGROUND: The nationwide epidemiological data on Kounis Syndrome (KS), still remains indistinct in the United States (US) after it was first reported in 1991. METHODS: We assessed the prevalence of KS among patients primarily hospitalized for allergic/hypersensitivity/anaphylactic reactions. We then compared baseline demographics, comorbidities, and outcomes of KS with patients with only allergic/hypersensitivity/anaphylactic reactions using the National Inpatient Sample, 2007-2014. RESULTS: The cohort comprised of 235,420 patients primarily hospitalized with allergy/hypersensitivity/anaphylactic reactions. Of these, 2616 [1.1%; 0.2% unstable angina, 0.2% ST-elevation myocardial infarction & 0.7% non-ST-elevation myocardial infarction] patients experienced ACS and were identified as having KS. Patients with KS were older (mean 65.9 ± 14.1 vs. 57.2 ± 17.8 yrs), more often White (71.1% vs. 58.6%), male (46.4% vs. 39.9%) and Medicare enrollees (58.9% vs. 41.5%) admitted non-electively (96.8% vs. 95.3%) as compared to non-KS group (p < 0.001). The hospitalizations with KS demonstrated higher all-cause in-hospital mortality (7.0% vs. 0.4%, p < 0.001), prolonged hospitalization stay (mean 5.8 ± 6.0 vs. 3.0 ± 3.9 days, p < 0.001), higher hospitalization charges ($52,656 vs. $20,487, p < 0.001) and more frequent transfers to other facilities. The rates of stroke (1.0% vs. 0.2%), arrhythmias (30.4% vs. 12.4%), venous thromboembolism (1.6% vs. 1.0%), and diagnostic and therapeutic coronary interventions were also found to be significantly higher in patients with KS (p < 0.05). Patients with KS had increased odds of in-hospital mortality [unadjusted OR: 18.52; 95% CI: 15.74-21.80, p < 0.001 & adjusted OR: 9.74, 95% CI: 8.08-11.76, p < 0.001] compared to non-KS group. CONCLUSIONS: Overall US prevalence of KS among patients hospitalized for allergic/hypersensitivity/anaphylactic reactions is 1.1% with a subsequent all-cause inpatient mortality rate of 7.0%.
BACKGROUND: The nationwide epidemiological data on Kounis Syndrome (KS), still remains indistinct in the United States (US) after it was first reported in 1991. METHODS: We assessed the prevalence of KS among patients primarily hospitalized for allergic/hypersensitivity/anaphylactic reactions. We then compared baseline demographics, comorbidities, and outcomes of KS with patients with only allergic/hypersensitivity/anaphylactic reactions using the National Inpatient Sample, 2007-2014. RESULTS: The cohort comprised of 235,420 patients primarily hospitalized with allergy/hypersensitivity/anaphylactic reactions. Of these, 2616 [1.1%; 0.2% unstable angina, 0.2% ST-elevation myocardial infarction & 0.7% non-ST-elevation myocardial infarction] patients experienced ACS and were identified as having KS. Patients with KS were older (mean 65.9 ± 14.1 vs. 57.2 ± 17.8 yrs), more often White (71.1% vs. 58.6%), male (46.4% vs. 39.9%) and Medicare enrollees (58.9% vs. 41.5%) admitted non-electively (96.8% vs. 95.3%) as compared to non-KS group (p < 0.001). The hospitalizations with KS demonstrated higher all-cause in-hospital mortality (7.0% vs. 0.4%, p < 0.001), prolonged hospitalization stay (mean 5.8 ± 6.0 vs. 3.0 ± 3.9 days, p < 0.001), higher hospitalization charges ($52,656 vs. $20,487, p < 0.001) and more frequent transfers to other facilities. The rates of stroke (1.0% vs. 0.2%), arrhythmias (30.4% vs. 12.4%), venous thromboembolism (1.6% vs. 1.0%), and diagnostic and therapeutic coronary interventions were also found to be significantly higher in patients with KS (p < 0.05). Patients with KS had increased odds of in-hospital mortality [unadjusted OR: 18.52; 95% CI: 15.74-21.80, p < 0.001 & adjusted OR: 9.74, 95% CI: 8.08-11.76, p < 0.001] compared to non-KS group. CONCLUSIONS: Overall US prevalence of KS among patients hospitalized for allergic/hypersensitivity/anaphylactic reactions is 1.1% with a subsequent all-cause inpatient mortality rate of 7.0%.
Authors: Nicholas G. Kounis; Ioanna Koniari; Dimitrios Velissaris; George Tzanis; George Hahalis Journal: Balkan Med J Date: 2019-06-14 Impact factor: 2.021
Authors: Anthony R Prisco; Jason Allen; Alejandra Gutierrez; Alexander Zanotto; Demetris Yannopoulos; Jeremy Markowitz; Jason A Bartos Journal: JACC Case Rep Date: 2020-04-15